Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2021 | Metastasis | Research

Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis

Authors: Tuanhe Sun, Kang Li, Gang Xu, Kun Zhu, Qiong Wang, Chengxue Dang, Dawei Yuan

Published in: World Journal of Surgical Oncology | Issue 1/2021

Abstract

Background

The prognosis of patients with colorectal cancer and peritoneal metastasis (CRC-PM) after incomplete cytoreductive surgery (CRS) or palliative surgery is poor. Novel and effective therapies are urgently needed. This study aimed to assess the effects of palliative postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with CRC-PM.

Methods

This retrospective study included patients with CRC-PM at the First Affiliated Hospital of Xi’an Jiaotong University in 05/2014–05/2019. Observation indicators included overall survival (OS), ascites-free survival, peritoneal cancer index (PCI), and completeness of cytoreduction (CC). Kaplan-Meier survival curves and multivariable Cox regression models were used to determine the factors associated with OS and ascites-free survival. The ascites-specific quality of life (QoL) was measured using the Functional Assessment of Chronic Illness Therapy-Ascites Index (FACIT-AI).

Results

Eighty-two patients were included, including 37 and 45 in the HIPEC and non-HIPEC groups, respectively. Mean OS was 10.3±3.7 (95% CI 9.5–11.2) months. Multivariable Cox proportional hazard regression suggested that PCI (HR=6.086, 95% CI 3.187–11.620, P < 0.0001) was independently associated with OS. The degree of ascites (HR=2.059, 95% CI 1.412–3.005, P < 0.0001), PCI (HR=6.504, 95% CI 2.844–14.875, P < 0.0001), and HIPEC (HR=0.328, 95% CI 0.191–0.562, P < 0.0001) were independently associated with ascites-free survival. In patients with survival >6 months, postoperative ascites-specific QoL was significantly improved after HIPEC compared with the non-HIPEC group (P < 0.001). Oxaliplatin-based HIPEC significantly increased the rates of neutropenia and peripheral neurotoxicity (both P < 0.05).

Conclusion

These data indicate that postoperative oxaliplatin-based HIPEC might help increase ascites-free survival in CRC-PM patients after incomplete CRS or palliative surgery, with improved QoL after 6 months of follow-up.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64. https://doi.org/10.3322/caac.21601.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray FI, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRef

Jayne D, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–50. https://doi.org/10.1046/j.1365-2168.2002.02274.x.CrossRefPubMed

NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon cancer. Version 4.2020. Fort Washington: National Comprehensive Cancer Network; 2020.

NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Rectal cancer. Version 6.2020. Fort Washington: National Comprehensive Cancer Network; 2020.

Franko J, Shi Q, Meyers J, Maughan T, Adams R, Seymour M, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–19. https://doi.org/10.1016/S1470-2045(16)30500-9.CrossRefPubMed

Desai JP, Moustarah F. Cancer, Peritoneal Metastasis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2020.

10.

Halkia E, Spiliotis J, Sugarbaker P. Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract. 2012;2012:541842.CrossRef

11.

Van Driel WJ, Koole SN, Sikorska K, Van Leeuwen JHS, Schreuder HWR, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618.CrossRefPubMed

12.

Bonnot P-E, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028–40. https://doi.org/10.1200/JCO.18.01688.CrossRefPubMed

13.

Chua T, Moran B, Sugarbaker P, Levine E, Glehen O, Gilly F, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56. https://doi.org/10.1200/JCO.2011.39.7166.CrossRefPubMed

14.

Elias D, Gilly F, Boutitie F, Quenet F, Bereder J, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63–8. https://doi.org/10.1200/JCO.2009.23.9285.CrossRefPubMed

15.

Nassour I, Polanco PM. Current management of peritoneal carcinomatosis from colorectal cancer: the role of cytoreductive surgery and hyperthermic peritoneal chemoperfusion. Curr Colorectal Cancer Rep. 2017;13(2):144–53. https://doi.org/10.1007/s11888-017-0361-x.CrossRefPubMedPubMedCentral

16.

Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). J Gastrointest Oncol. 2016;7(1):3–9. https://doi.org/10.3978/j.issn.2078-6891.2015.101.CrossRefPubMedPubMedCentral

17.

Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy. J Gastrointest Oncol. 2016;7:45–57.CrossRef

18.

Lam JY, McConnell YJ, Rivard JD, Temple WJ, Mack LA. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg. 2015;210(3):424–30. https://doi.org/10.1016/j.amjsurg.2015.03.008.CrossRefPubMed

19.

Verwaal V, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2.CrossRefPubMed

20.

Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7, vol. 36; 2018.

21.

Kasi A, Paluri R. Practice changing updates in gastro-intestinal oncology 2018. J Adv Med Pharm Sci. 2019;19(2):1–9. https://doi.org/10.9734/JAMPS/2018/46063.CrossRef

22.

Klaver CEL, Wisselink DD, Punt CJ, Snaebjornsson P, Crezee J, Aalbers A, et al. Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: primary outcome of the COLOPEC multicenter randomized trial. In: American Society of Clinical Oncology; 2019.

23.

Glehen O, Kwiatkowski F, Sugarbaker P, Elias D, Levine E, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92. https://doi.org/10.1200/JCO.2004.10.012.CrossRefPubMed

24.

Kamada Y, Hida K, Ishibashi H, Sako S, Mizumoto A, Ichinose M, et al. Thirty-three long-term survivors after cytoreductive surgery in patients with peritoneal metastases from colorectal cancer: a retrospective descriptive study. World J Surg Oncol. 2021;19(1):31. https://doi.org/10.1186/s12957-021-02145-1.CrossRefPubMedPubMedCentral

25.

National Health Commission Of The People’s Republic Of C. National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version). Chin J Cancer Res. 2020;32:415–45.CrossRef

26.

Krishnamurthy S, Balasubramaniam R. Role of imaging in peritoneal surface malignancies. Indian J Surg Oncol. 2016;7(4):441–52. https://doi.org/10.1007/s13193-016-0539-8.CrossRefPubMedPubMedCentral

27.

Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Melis M, Malik E, et al. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol. 2018;29(4):e47. https://doi.org/10.3802/jgo.2018.29.e47.CrossRefPubMedPubMedCentral

28.

Sugarbaker P. Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Tumori. 2001;87(4):S3–5.CrossRef

29.

Jacquet P, Sugarbaker P. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. https://doi.org/10.1007/978-1-4613-1247-5_23.CrossRefPubMed

30.

Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38(1):258–66. https://doi.org/10.1053/jhep.2003.50315.CrossRefPubMed

31.

Cella D, Neubauer N, Thomas J, Kutner J, Seiden MV. The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites. Gynecol Oncol. 2013;128(2):187–90. https://doi.org/10.1016/j.ygyno.2012.11.013.CrossRefPubMed

32.

Services USDoHaH: Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017.

33.

Sadeghi B, Arvieux C, Glehen O, Beaujard A, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–63. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O.CrossRefPubMed

34.

Bushati M, Rovers K, Sommariva A, Sugarbaker P, Morris D, Yonemura Y, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). J Eur J Surg Oncol. 2018;44(12):1942–8. https://doi.org/10.1016/j.ejso.2018.07.003.CrossRef

35.

Polanco P, Ding Y, Knox J, Ramalingam L, Jones H, Hogg M, et al. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol. 2015;22(5):1673–9. https://doi.org/10.1245/s10434-014-4111-x.CrossRefPubMed

36.

Kuijpers A, Aalbers A, Nienhuijs S, de Hingh I, Wiezer M, van Ramshorst B, et al. Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. Surg. 2015;39:453–60.

37.

Goéré D, Malka D, Tzanis D, Gava V, Boige V, Eveno C, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257(6):1065–71. https://doi.org/10.1097/SLA.0b013e31827e9289.CrossRefPubMed

38.

Chang M-C, Chen J-H, Liang J-A, Huang W-S, Cheng K-Y, Kao C-H. PET or PET/CT for detection of peritoneal carcinomatosis: a meta-analysis. Clin Nucl Med. 2013;38(8):623–9. https://doi.org/10.1097/RLU.0b013e318299609f.CrossRefPubMed

39.

Kim S-J, Lee S-W. Diagnostic accuracy of 18F-FDG PET/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis. Br J Radiol. 2018;91(1081):20170519. https://doi.org/10.1259/bjr.20170519.CrossRefPubMed

40.

Jiao J, Li C, Yu G, Zhang L, Shi X, Yan J, et al. Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites. World J Surg Oncol. 2020;18(1):180. https://doi.org/10.1186/s12957-020-01956-y.CrossRefPubMedPubMedCentral

41.

Wong JSM, Tan GHC, Chia CS, Ong J, Ng WY, Teo MCC. The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2020;18(1):10. https://doi.org/10.1186/s12957-020-1784-4.CrossRefPubMedPubMedCentral

42.

Saif MW, Siddiqui IA, Sohail MA. Management of ascites due to gastrointestinal malignancy. Ann Saudi Med. 2009;29(5):369–77. https://doi.org/10.4103/0256-4947.55167.CrossRefPubMedPubMedCentral

43.

Piawah S, Venook A. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139–47. https://doi.org/10.1002/cncr.32163.CrossRefPubMed

Title: Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis
Authors: Tuanhe Sun
Kang Li
Gang Xu
Kun Zhu
Qiong Wang
Chengxue Dang
Dawei Yuan
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Ascites
Colorectal Cancer
Colorectal Cancer
Cytostatic Therapy
Peritoneal Cancer
Peritoneal Carcinomatosis
Published in: World Journal of Surgical Oncology / Issue 1/2021
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-021-02320-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Clinical-MRI radiomics enables the prediction of preoperative cerebral spinal fluid dissemination in children with medulloblastoma

The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors

Introduction of gasless laparoscopic surgery as a minimally invasive procedure for endometrial cancer and its usefulness from the viewpoint of the learning curve

The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone

Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer